# Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

> **NCT03504566** · PHASE4 · WITHDRAWN · sponsor: **Steno Diabetes Center Copenhagen**

## Conditions studied

- Diabetic Nephropathy Type 2

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Empagliflozin
- **DRUG:** Telmisartan
- **DRUG:** Sulodexide

## Key facts

- **NCT ID:** NCT03504566
- **Lead sponsor:** Steno Diabetes Center Copenhagen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-11-15
- **Primary completion:** 2019-06-01
- **Final completion:** 2019-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Registered and published incorrectly
- **Last updated:** 2018-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03504566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03504566, "Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03504566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*